Abstract:Background and Objective: Paraneoplastic neurological syndromes (PNS) are a group of rare syndromes associated with immunopathological process and tumors. Paraneoplastic autoantibodies are important for the diagnosis of PNS and for searching for underlying tumors. With the development of detection methods and discovery of new autoantibodies, the 2004 guidelines on PNS have recently been updated by a worldwide PNS-Care expert group. For clinicians, proper testing methods and testing results explanation are important for the diagnosis and treatment of PNS. This review aims to review the detection of paraneoplastic autoantibodies and the significance of testing results.Methods: We summarize the studies on detection methods, association of autoantibodies and PNS or tumors, particularly the guidelines of PNS.Key Content and Findings: Antibodies are divided into 3 groups in the context of PNS according to the frequency of cancer association regardless of their eventual pathogenic effect. Instead of well-characterized antibodies and partially-characterized antibodies, high-risk antibodies, intermediate risk antibodies and lower risk antibodies were applied. According to the location of recognized antigens, these autoantibodies are divided as anti-intracellular antigen antibodies and neuronal surface antibodies (NSAbs). Tissue-based assays is recommended as screening method for paraneoplastic antibodies. Moreover, this method is helpful to discover new autoantibodies. A combination of a screening method [tissue-based assays (TBA)] and a confirmatory test [immunoblot and cell-based assay (CBA)] can improve sensitivity and specificity of the tests. Many PNSs are associated with specific antineuronal antibodies, but there is considerable diversity. Some autoantibodies are markers of specific neurological syndromes. Paraneoplastic antibodies are often specific for the PNS-associated tumor rather than for a particular neurological syndrome.Conclusions: Diagnosis of PNS depends on integrated analysis of clinical manifestations and auxiliary examinations. During diagnosis, selection of candidate antibodies for testing is challenging due to the varying clinical phenotypes and tumors associated with a given antibody. Broad antibody panels are more likely to capture causative antibodies and should be considered. According to different subtypes of autoantibodies, specific tumors or PNS should be considered. However, antibody titers, including cerebrospinal fluid (CSF) titers, should not be the primary driver of treatment decisions.

Tell-tale immune-related neurological syndromes: Should we look for and underlying low-grade B-cell lymphoma? A retrospective study on 12 cases

Primary central nervous system lymphoma mimicking recurrent depressive disorder: A case report.

The role of peripheral immunity in ALS: a population-based study

Neuroinflammation preceding primary central nervous system lymphoma (PCNSL) - Case reports and literature review

Intraparenchymal low-grade B-cell lymphomas of the central nervous system: Clinicopathologic and molecular analysis of three cases and a review of the literature

Immune-mediated diseases involving central and peripheral nervous systems

From Biology to Treatment of Monoclonal Gammopathies of Neurological Significance

Detection of paraneoplastic antibodies and their significance in paraneoplastic neurologic syndromes: a narrative review

Paraneoplastic Neurological Syndromes of the Central Nervous System: Pathophysiology, Diagnosis, and Treatment

Unveiling the Clinical and Imaging Signatures of Intravascular Lymphoma of the Central Nervous System: A Multicentric Cohort Study

Pathology and new insights in central nervous system lymphomas

Bios-03. Clinical Presentation, Management, And Outcome In Neurolymphomatosis: A Systematic Review And Analysis Of Individual Patient Data From 459 Cases

Primary diffuse large B-cell lymphoma of the central nervous system identified with CSF biomarkers

An Eight-Year Single-Center Experience

Clinical Presentation, Management, and Outcome in Neurolymphomatosis: A Systematic Review

Primary central nervous system lymphoma: a series report and literature review

Neurological autoimmunity in patients with non‐pulmonary neuroendocrine neoplasms: clinical manifestations and neural autoantibody profiles

Systemic relapses of primary CNS lymphomas (PCNSL): a LOC network study

Mechanisms of immune tolerance breakdown in paraneoplastic neurological syndromes

BIOM-65. NEW BIOMARKERS FOR THE DIAGNOSIS OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA IN CEREBROSPINAL FLUID: AN EXPLORATORY MULTICENTER RETROSPECTIVE COHORT STUDY

Anti-Ma2-associated limbic encephalitis with coexisting chronic inflammatory demyelinating polyneuropathy in a patient with non-Hodgkin lymphoma: A case report.